Connection

MENASHE BAR ELI to Melanoma

This is a "connection" page, showing publications MENASHE BAR ELI has written about Melanoma.
Connection Strength

5.631
  1. Why is melanoma so metastatic? Pigment Cell Melanoma Res. 2014 Jan; 27(1):19-36.
    View in: PubMed
    Score: 0.140
  2. Crossing the junction in the gap of melanoma brain metastasis. Pigment Cell Melanoma Res. 2013 Jul; 26(4):435-7.
    View in: PubMed
    Score: 0.135
  3. Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev. 2012 Dec; 31(3-4):621-32.
    View in: PubMed
    Score: 0.132
  4. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 2012 Nov 15; 72(22):5757-66.
    View in: PubMed
    Score: 0.130
  5. The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res. 2012 Sep; 25(5):592-601.
    View in: PubMed
    Score: 0.128
  6. PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res. 2011 Nov 01; 71(21):6561-6.
    View in: PubMed
    Score: 0.122
  7. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res. 2011 Aug; 21(4):357-63.
    View in: PubMed
    Score: 0.120
  8. Searching for the 'melano-miRs': miR-214 drives melanoma metastasis. EMBO J. 2011 May 18; 30(10):1880-1.
    View in: PubMed
    Score: 0.118
  9. Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res. 2011 May 15; 71(10):3494-504.
    View in: PubMed
    Score: 0.117
  10. The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target. Oncotarget. 2011 Jan-Feb; 2(1-2):8-17.
    View in: PubMed
    Score: 0.115
  11. Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proc Natl Acad Sci U S A. 2011 Jan 11; 108(2):626-31.
    View in: PubMed
    Score: 0.115
  12. Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol. 2011 Apr; 21(2):83-8.
    View in: PubMed
    Score: 0.115
  13. CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One. 2010 Aug 27; 5(8):e12452.
    View in: PubMed
    Score: 0.113
  14. Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem. 2009 Oct 16; 284(42):28845-55.
    View in: PubMed
    Score: 0.105
  15. Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res. 2009 Aug 15; 69(16):6730-7.
    View in: PubMed
    Score: 0.105
  16. Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem. 2009 Sep 18; 284(38):26194-206.
    View in: PubMed
    Score: 0.104
  17. Inflammation and melanoma metastasis. Pigment Cell Melanoma Res. 2009 Jun; 22(3):257-67.
    View in: PubMed
    Score: 0.102
  18. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol. 2008 Dec; 173(6):1839-52.
    View in: PubMed
    Score: 0.099
  19. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008 Nov 01; 68(21):9078-86.
    View in: PubMed
    Score: 0.099
  20. Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther. 2008 Jul; 7(7):997-1003.
    View in: PubMed
    Score: 0.097
  21. Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol. 2008; 9(5):307-11.
    View in: PubMed
    Score: 0.094
  22. Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev. 2007 Dec; 26(3-4):359-71.
    View in: PubMed
    Score: 0.093
  23. The HOG-GLI face of melanoma. Pigment Cell Res. 2007 Oct; 20(5):341-2.
    View in: PubMed
    Score: 0.092
  24. Searching for the Achilles' heel of melanoma cells: new treatment modalities. Pigment Cell Melanoma Res. 2008 Oct; 21(5):505-6.
    View in: PubMed
    Score: 0.091
  25. ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Res. 2007 Jun 01; 67(11):5258-66.
    View in: PubMed
    Score: 0.090
  26. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res. 2006 Nov 15; 12(22):6709-15.
    View in: PubMed
    Score: 0.087
  27. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther. 2007 Feb; 14(4):316-23.
    View in: PubMed
    Score: 0.086
  28. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res. 2006 Oct; 19(5):395-405.
    View in: PubMed
    Score: 0.086
  29. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol. 2007 Feb; 127(2):387-93.
    View in: PubMed
    Score: 0.085
  30. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 2005 Dec 01; 65(23):11185-92.
    View in: PubMed
    Score: 0.081
  31. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem. 2006 Feb 03; 281(5):2911-22.
    View in: PubMed
    Score: 0.081
  32. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res. 2005 Feb 01; 65(3):692-7.
    View in: PubMed
    Score: 0.077
  33. Regulation of gene expression in melanoma: new approaches for treatment. J Cell Biochem. 2005 Jan 01; 94(1):25-38.
    View in: PubMed
    Score: 0.076
  34. Construction and expression of intracellular anti-ATF-1 single chain Fv fragment: a modality to inhibit melanoma tumor growth and metastasis. Methods. 2004 Oct; 34(2):233-9.
    View in: PubMed
    Score: 0.075
  35. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol. 2004 Jun 01; 22(11):2092-100.
    View in: PubMed
    Score: 0.073
  36. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol. 2004 Feb; 122(2):400-5.
    View in: PubMed
    Score: 0.071
  37. Gene expression profiling of human cutaneous melanoma: are we there yet? Cancer Biol Ther. 2004 Jan; 3(1):121-3.
    View in: PubMed
    Score: 0.071
  38. Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem. 2003 Nov 21; 278(47):46632-42.
    View in: PubMed
    Score: 0.070
  39. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003 Aug; 2(8):753-63.
    View in: PubMed
    Score: 0.069
  40. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene. 2003 May 19; 22(20):3130-7.
    View in: PubMed
    Score: 0.068
  41. Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis. 2003; 20(3):251-63.
    View in: PubMed
    Score: 0.066
  42. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 01; 62(17):5106-14.
    View in: PubMed
    Score: 0.065
  43. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther. 2002 Sep-Oct; 1(5):459-65.
    View in: PubMed
    Score: 0.065
  44. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul; 161(1):125-34.
    View in: PubMed
    Score: 0.064
  45. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene. 2001 Jun 07; 20(26):3363-75.
    View in: PubMed
    Score: 0.059
  46. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res. 2001 Apr; 14(2):78-85.
    View in: PubMed
    Score: 0.059
  47. Targeting the ATF-1/CREB transcription factors by single chain Fv fragment in human melanoma: potential modality for cancer therapy. Crit Rev Immunol. 2001; 21(1-3):275-86.
    View in: PubMed
    Score: 0.058
  48. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol Cell Biochem. 2000 Sep; 212(1-2):19-28.
    View in: PubMed
    Score: 0.056
  49. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene. 2000 May 18; 19(22):2721-30.
    View in: PubMed
    Score: 0.055
  50. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res. 1999 Jul; 19(7):697-703.
    View in: PubMed
    Score: 0.052
  51. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology. 1999; 67(1):12-8.
    View in: PubMed
    Score: 0.050
  52. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev. 1999; 18(3):377-85.
    View in: PubMed
    Score: 0.050
  53. Molecular changes in human melanoma metastasis. Histol Histopathol. 1998 10; 13(4):1225-31.
    View in: PubMed
    Score: 0.049
  54. CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem. 1998 Sep 18; 273(38):24884-90.
    View in: PubMed
    Score: 0.049
  55. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 1998 Aug 03; 17(15):4358-69.
    View in: PubMed
    Score: 0.049
  56. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem. 1998 Jun 26; 273(26):16501-8.
    View in: PubMed
    Score: 0.048
  57. Molecular mechanisms of melanoma metastasis. J Cell Physiol. 1997 Nov; 173(2):275-8.
    View in: PubMed
    Score: 0.046
  58. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene. 1997 Oct 23; 15(17):2069-75.
    View in: PubMed
    Score: 0.046
  59. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 1997 Oct; 151(4):1105-13.
    View in: PubMed
    Score: 0.046
  60. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res. 1997 Jun 01; 57(11):2295-303.
    View in: PubMed
    Score: 0.045
  61. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene. 1996 Dec 05; 13(11):2339-47.
    View in: PubMed
    Score: 0.043
  62. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res. 1996 Dec; 2(12):1969-79.
    View in: PubMed
    Score: 0.043
  63. A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res. 1996 Jan 15; 56(2):254-8.
    View in: PubMed
    Score: 0.041
  64. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene. 1995 Oct 05; 11(7):1399-402.
    View in: PubMed
    Score: 0.040
  65. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res. 1995 Aug 15; 55(16):3669-74.
    View in: PubMed
    Score: 0.040
  66. The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis. Int J Cancer. 2015 Mar 15; 136(6):1296-307.
    View in: PubMed
    Score: 0.037
  67. Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res. 1994 Sep-Oct; 14(5A):1759-65.
    View in: PubMed
    Score: 0.037
  68. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest. 2013 Jun; 123(6):2703-18.
    View in: PubMed
    Score: 0.034
  69. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 2013 Jul 15; 73(14):4383-94.
    View in: PubMed
    Score: 0.034
  70. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res. 1993 Feb; 3(1):35-41.
    View in: PubMed
    Score: 0.033
  71. Chitosan hydrogel for localized gene silencing. Cancer Biol Ther. 2011 May 01; 11(9):839-45.
    View in: PubMed
    Score: 0.029
  72. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 2009 Oct 01; 69(19):7538-47.
    View in: PubMed
    Score: 0.026
  73. A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 2008 Oct 15; 68(20):8419-28.
    View in: PubMed
    Score: 0.025
  74. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 02; 99(5):734-40.
    View in: PubMed
    Score: 0.024
  75. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell. 2007 May; 11(5):447-60.
    View in: PubMed
    Score: 0.022
  76. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res. 2007 Feb 15; 67(4):1502-12.
    View in: PubMed
    Score: 0.022
  77. Transcriptional regulation of KiSS-1 gene expression in metastatic melanoma by specificity protein-1 and its coactivator DRIP-130. Oncogene. 2007 Mar 15; 26(12):1739-47.
    View in: PubMed
    Score: 0.021
  78. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 2004 Oct 15; 64(20):7361-9.
    View in: PubMed
    Score: 0.019
  79. Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. 2004 Jan 01; 64(1):146-51.
    View in: PubMed
    Score: 0.018
  80. Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res. 1998 Jul 01; 58(13):2733-6.
    View in: PubMed
    Score: 0.012
  81. Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer. 1997 Nov 27; 73(5):769-74.
    View in: PubMed
    Score: 0.012
  82. Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol. 2012 May; 180(5):2170-81.
    View in: PubMed
    Score: 0.008
  83. Expression of ki-ras oncogene in tumor cell variants exhibiting different metastatic capabilities. Int J Cancer. 1985 Feb 15; 35(2):227-30.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.